Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (361-370 of 580) with videos related to

Pageof 58
Sort By:
Cancer Discovery|March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor ResistanceMiles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.
The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Oncoscience|May 24, 2021
Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancerMargarite D Matossian, Van T Hoang, Hope E Burks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, et al.
Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of the National Cancer Institute|February 7, 2016
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant MelanomaFrancesco Sabbatino, Yangyang Wang, Giosuè Scognamiglio, et al.
Science Signaling|September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growthJuxiang Cao, Xiangpeng Dai, Lixin Wan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Travel Medicine and Infectious Disease|June 5, 2012
Recommendations for the practice of travel medicineJ H Chiodini, E Anderson, C Driver, et al.
The Oncologist|February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic ControlChristopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
Pageof 58

Showing results (361-370 of 580) with videos related to

Sort By:
Pageof 58
Cancer Discovery|March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor ResistanceMiles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.
The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Oncoscience|May 24, 2021
Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancerMargarite D Matossian, Van T Hoang, Hope E Burks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, et al.
Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of the National Cancer Institute|February 7, 2016
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant MelanomaFrancesco Sabbatino, Yangyang Wang, Giosuè Scognamiglio, et al.
Science Signaling|September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growthJuxiang Cao, Xiangpeng Dai, Lixin Wan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Travel Medicine and Infectious Disease|June 5, 2012
Recommendations for the practice of travel medicineJ H Chiodini, E Anderson, C Driver, et al.
The Oncologist|February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic ControlChristopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
Pageof 58